Fluidigm Corp. (South San Francisco, CA, USA) has announced that sales of its flagship BioMark system for genetic analysis have now surpassed 100 cumulative units in the field. In addition to real-time qPCR, the BioMark system also offers digital PCR, gene expression, and genotyping capabilities for researchers. The versatility, throughput, and ease-of-use of the system, combined with the IFC technology, enable leading research labs across the United States, Europe, Japan, and Asia to perform advanced research on cancer, stem cells, noninvasive prenatal diagnostics, as well as fishery management of wild salmon and much more.

“This is Fluidigm’s first system to ship more than 100 units and I’m extremely proud of the accomplishment. Achieving this shipment milestone indicates that we are making a contribution to life-science research and to applied markets already, yet we’ve only just begun,” said Gajus Worthington, president and chief executive officer of Fluidigm.

Fluidigm’s BioMark system was introduced in November 2006.

Fluidigm develops, manufactures, and markets proprietary IFC systems that significantly improve productivity in life science research. Fluidigm’s IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These “integrated circuits for biology” are made possible by miniaturizing and integrating liquid-handling components on a single IFC. Fluidigm products have not been cleared or approved by the U.S. Food and Drug Administration (FDA) for use as a diagnostic and are only available for research use.

Related Links:
Fluidigm